Celcuity Finalizes $500M Convertible Senior Notes Offering at 40% Premium Conversion Price
Summary
Celcuity Inc. finalized a $500 million convertible senior notes offering with a conversion price 40% above its current stock price, securing significant capital to repay debt and fund its drug development and commercialization efforts.
Key Events
-
$500M Convertible Senior Notes Offering Finalized
Celcuity Inc. priced and finalized its offering of $500 million aggregate principal amount of 0.250% Convertible Senior Notes due 2032, with an option for underwriters to purchase an additional $75 million.
-
Premium Conversion Price Demonstrates Confidence
The initial conversion price is set at approximately $124.53 per share, representing a substantial 40% premium over the common stock's closing price of $88.95 on June 3, 2026.
-
Repayment of Secured Debt and Extended Cash Runway
Net proceeds of approximately $484.3 million will be used to repay $137.9 million in secured debt and fund working capital, clinical trials, and commercial launch expenditures, extending the company's financial runway into 2028.
-
Potential Future Dilution
If all notes were converted at the initial conversion rate, it would result in approximately 4.02 million new shares, representing a potential dilution of about 8.30% to existing shareholders based on current outstanding shares.
Analysis
Celcuity Inc. has finalized the terms for its $500 million offering of 0.250% Convertible Senior Notes due 2032. This offering, which could increase to $575 million if the over-allotment option is fully exercised, provides substantial capital for the clinical-stage biotechnology company. The initial conversion price of approximately $124.53 per share represents a significant 40% premium over the common stock's closing price of $88.95 on June 3, 2026, indicating strong investor confidence in future stock appreciation. The net proceeds of approximately $484.3 million will be primarily used to repay $137.9 million in outstanding secured debt, improving the company's balance sheet, with the remainder allocated to working capital and general corporate purposes, including funding critical clinical trials and commercial launch preparations for gedatolisib. This capital infusion is particularly important given the company's recent positive Phase 3 trial results and upcoming FDA Priority Review PDUFA date of July 17, 2026, providing a longer cash runway for its strategic initiatives.
At the time of this filing, CELC was trading at $88.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $11.28 to $151.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.